DOCSLIB.ORG

IL-1 Processing, Signaling and Its Role in Cancer Progression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IL-1 Processing, Signaling and Its Role in Cancer Progression cells Review IL-1α Processing, Signaling and Its Role in Cancer Progression Jing Wen Chiu †, Zuhairah Binte Hanafi †, Lionel Chin Yong Chew † , Yu Mei * and Haiyan Liu * Immunology Programme, Department of Microbiology and Immunology, Life Sciences Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456, Singapore; [email protected] (J.W.C.); [email protected] (Z.B.H.); [email protected] (L.C.Y.C.) * Correspondence: [email protected] (Y.M.); [email protected] (H.L.); Tel.: +65-90878606 (Y.M.); +65-65166661 (H.L.); Fax: +65-67782684 (H.L.) † Equal contribution. Abstract: Interleukin-1α (IL-1α) is a major alarmin cytokine which triggers and boosts the inflam- matory responses. Since its discovery in the 1940s, the structure and bioactivity of IL-1α has been extensively studied and emerged as a vital regulator in inflammation and hematopoiesis. IL-1α is translated as a pro-form with minor bioactivity. The pro-IL-1α can be cleaved by several proteases to generate the N terminal and C terminal form of IL-1α. The C terminal form of IL-1α (mature form) has several folds higher bioactivity compared with its pro-form. IL-1α is a unique cytokine which could localize in the cytosol, membrane, nucleus, as well as being secreted out of the cell. However, the processing mechanism and physiological significance of these differentially localized IL-1α are still largely unknown. Accumulating evidence suggests IL-1α is involved in cancer pathogenesis. The role of IL-1α in cancer development is controversial as it exerts both pro- and anti-tumor roles in different cancer types. Here, we review the recent development in the processing and signaling of IL-1α and summarize the functions of IL-1α in cancer development. Keywords: interleukin-1α; IL-1R; protease; cancer Citation: Chiu, J.W.; Binte Hanafi, Z.; Chew, L.C.Y.; Mei, Y.; Liu, H. IL-1α 1. Introduction Processing, Signaling and Its Role in Interleukin-1 (IL-1) was first reported in 1943 when Valy Menkin isolated a pyrogenic Cancer Progression. Cells 2021, 10, 92. euglobulin from inflammatory exudates. This pyrogenic euglobulin, later named as pyrexin, https://doi.org/10.3390/ was found to be heat stable and induce biphasic fevers preceded by a marked leukopenia cells10010092 and significant latent period [1,2]. Since then, this substance has been identified and reported by scientists in different research fields and were given different names based on Received: 1 December 2020 its biological properties, such as endogenous pyrogen, leukocytic endogenous mediator, Accepted: 5 January 2021 lymphocyte activating factor, hemopoietin-1, mononuclear cell factor, proteolysis inducing Published: 7 January 2021 factor, catabolin and osteoclast activating factor [3]. In 1974, Dinarello et al. identified two chemically and biologically distinctive pyrogens derived from monocytes and neutrophils, Publisher’s Note: MDPI stays neu- respectively [4]. Another ten years later, these pyrogens were cloned from both human and tral with regard to jurisdictional clai- mouse and named as Interleukin-1 [5,6]. One year later, Carl J. March et al. successfully ms in published maps and institutio- isolated these two DNA encoding proteins sharing human IL-1 activity, and named them nal affiliations. as IL-1α and IL-1β, respectively [7]. Since then, the function of IL-1β has been extensively studied, while the biological processing and function of IL-1α were less well studied. In this review, we summarize the current understanding of IL-1α processing, signaling, function Copyright: © 2021 by the authors. Li- and its role in cancer progression. censee MDPI, Basel, Switzerland. This article is an open access article 2. The Biology of IL-1α distributed under the terms and con- 2.1. IL-1a Expression ditions of the Creative Commons At- IL-1α is constitutively expressed by many types of cells, including fibroblasts, hepato- tribution (CC BY) license (https:// cytes, keratinocytes, macrophages, dendritic cells, T cells, et cetera [8]. Although various creativecommons.org/licenses/by/ types of cells are known to produce IL-1α, endothelial and epithelial cells are the main 4.0/). Cells 2021, 10, 92. https://doi.org/10.3390/cells10010092 https://www.mdpi.com/journal/cells Cells 2021, 10, x FOR PEER REVIEW 2 of 19 Cells 2021, 10, 92 2 of 19 various types of cells are known to produce IL‐1α, endothelial and epithelial cells are the main source of IL‐1α under both physiological and pathological conditions. At steady state, the expressionsource level of IL-1 of ILα‐1underα is relatively both physiological low, whereas and upon pathological exposure conditions.to pathogens At steady state, or stress‐inducedthe stimulus, expression the level expression of IL-1 αofis IL relatively‐1α increases low, dramatically whereas upon to exposureinitiate in to‐ pathogens or flammatory responsesstress-induced [9]. stimulus, the expression of IL-1α increases dramatically to initiate inflam- matory responses [9]. 2.2. IL‐1α Processing 2.2. IL-1a Processing IL‐1α is translated into a 31‐kDa precursor form (pro‐IL‐1α). The pro‐IL‐1α contains IL-1α is translated into a 31-kDa precursor form (pro-IL-1α). The pro-IL-1α contains a nuclear localization signal (NLS) site which leads the pro‐IL‐1α translocation into the a nuclear localization signal (NLS) site which leads the pro-IL-1α translocation into the nucleus. IL‐1α also contains several post‐translational modification sites: (1) pro‐IL‐1α nucleus. IL-1α also contains several post-translational modification sites: (1) pro-IL-1α can can be phosphorylated at Ser90; (2) pro‐IL‐1α can be myristoylated at Lys82; and (3) be phosphorylated at Ser90; (2) pro-IL-1α can be myristoylated at Lys82; and (3) pro-IL-1α pro‐IL‐1α can be acetylated at Lys82 [10–13]. So far, the mechanisms and functions of can be acetylated at Lys82 [10–13]. So far, the mechanisms and functions of these post- these post‐translational modifications are not well understood. The pro‐IL‐1α could also translational modifications are not well understood. The pro-IL-1α could also be cleaved be cleaved by severalby several protease protease to a to17 a‐kDa 17-kDa mature mature form form and anda 16‐ akDa 16-kDa N terminal N terminal form form named as named as propiecepropiece [14]. [The14]. Themature mature form form of IL of‐1 IL-1α hasα has higher higher biology biology activity activity compared compared to the pro-IL- to the pro‐IL‐11α αasas its its binding affinityaffinity toto its its receptor receptor is is several several folds folds higher higher than than the the pro-IL-1 α [15]. So pro‐IL‐1α [15]. far,So far, elastase, elastase, cathepsin cathepsin G, proteinase-3, G, proteinase calpain,‐3, calpain, granzyme granzyme B, mast B, mast cell chymase, cell caspase-5, chymase, caspasecaspase-11‐5, caspase and‐11 thrombin and thrombin have been have identified been identified as the pro-IL-1 as the αprocleavage‐IL‐1α proteases [16] cleavage proteases(Figure [16]1 ).(Figure 1). Figure 1. OverviewFigure 1. Overview of IL-1α ofstructure. IL‐1α structure. Human Human IL-1α consistsIL‐1α consists of 271 of amino 271 amino acids acids including including an nuclear an nu‐ localization signal (NLS)clear domain. localization IL-1α signalcan be (NLS) cleaved domain. by various IL‐1α can proteases, be cleaved such by asvarious elastase, proteases, granzyme such B, as caspase-5, elastase, thrombin, chymase andgranzyme calpain. B, IL-1 caspaseα also‐5, undergoes thrombin, post-translational chymase and calpain. modification, IL‐1α also including undergoes acetylation, post‐translational myristoylation as well as phosphorylation.modification, including acetylation, myristoylation as well as phosphorylation. 2.2.1. Elastase, Cathepsin G and Proteinase‐3 2.2.1. Elastase, Cathepsin G and Proteinase-3 Neutrophils are the most abundant circulating leucocytes and play a vital role in Neutrophils are the most abundant circulating leucocytes and play a vital role in clearing pathogens through phagocytosis and destruction of microorganisms via granule clearing pathogens through phagocytosis and destruction of microorganisms via granule proteases [17]. The azurophil granule contains three major serine proteases: human leu‐ proteases [17]. The azurophil granule contains three major serine proteases: human cocyte elastase, cathepsin G and proteinase‐3 [18]. Elastase has long been recognized as leucocyte elastase, cathepsin G and proteinase-3 [18]. Elastase has long been recognized as IL‐1β‐processingIL-1 proteaseβ-processing and remains protease unclear and remains whether unclear it could whether also process it could IL‐ also1α [19]. process IL-1α [19]. In 2011, AfoninaIn et 2011, al. first Afonina reported et al. that first elastase reported could that cleavage elastase couldpro‐IL cleavage‐1α in vitro pro-IL-1 whenα in vitro when incubating the recombinantincubating the IL recombinant‐1α with elastase. IL-1α Thewith elastase elastase. cleaves The elastase IL‐1α at cleaves the Ala101 IL-1α at the Ala101 site, generatingsite, a more generating biological a more functional biological mature functional form mature of IL‐1 formα compared of IL-1α withcompared the with the pro- pro‐IL‐1α [20]. IL-1Recently,α [20]. the Recently, other two the neutrophils other two neutrophils-derived‐derived serine proteases: serine proteases:cathepsin G cathepsin G and and proteinase‐proteinase-33 have also been have implicated also been implicated to cleave pro to cleave‐IL‐1α pro-IL-1under theα under in vitro the incuin vitro‐ incubation bation condition.condition. Incubation Incubation of pro‐ ofIL‐ pro-IL-11α withα cathepsinwith cathepsin G and G andproteinase proteinase-3‐3 in vitroin vitro generated a generated a smallersmaller processed processed form form of of IL IL-1‐1α αcomparedcompared with with that that processed processed by by elastase [21].
Load more

Recommended publications
  • Data Sheet Huil36g (152 A.A.)
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin-36G (IL36G) is a pro-inflammatory cytokine that plays an important role in the pathophysiology of several diseases. IL36A, IL36B and IL36G (formerly IL1F6, IL1F8, and IL1F9) are IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36G is secreted when transfected into 293-T cells and could constitute part of an independent signaling system analogous to that of IL1A and IL1B receptor agonist and interleukin-1 receptor type I (IL1R1). Furthermore, IL36G also can function as an agonist of NFκB activation through the orphan IL1- receptor-related protein 2. Human IL36G (152 a.a.) shares 58%, 59%, 68% and 69% amino acid sequence identity with mouse, rat, bovine and equine IL36G, respectively, and 23-57% amino acid sequence identity with other family members. Catalog Number 1110-36F Product Name IL36G (IL-36 gamma), Human (152 a.a.) Recombinant Human Interleukin-36γ IL36G, IL36γ Interleukin 1 Homolog 1 (IL1H1) Interleukin 1-Related Protein 2 (IL1RP2) Interleukin 1 Family, Member 9 (IL1F9) Source Escherichia coli MW ~17.0 kDa (152 amino acids) Sequence SMCKPITGTI NDLNQQVWTL QGQNLVAVPR SDSVTPVTVA VITCKYPEAL EQGRGDPIYL GIQNPEMCLY CEKVGEQPTL QLKEQKIMDL YGQPEPVKPF LFYRAKTGRT STLESVAFPD WFIASSKRDQ PIILTSELGK SYNTAFELNI ND Accession Number Q9NZH8 Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The ED50 as determined by its ability to induce IL-8 secretion by human preadipocytes is less than 10 ng/ml, corresponding to a specific activity of >1 × 105 IU/mg.
    [Show full text]
  • Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
    Downloaded from http://cshperspectives.cshlp.org/ on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer Juming Yan,1,2 Mark J. Smyth,2,3 and Michele W.L. Teng1,2 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Queensland, Australia 2School of Medicine, University of Queensland, Herston 4006, Queensland, Australia 3Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Queensland, Australia Correspondence: [email protected] The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity. In this review, we discuss the role IL-12 and IL-23 plays in tumor biology from preclinical and clinical data. In particular, we discuss the mechanism by which IL-23 promotes tumor growth and metastases and how the IL-12/IL-23 axis of inflammation can be targeted for cancer therapy. he recognized interleukin (IL)-12 cytokine composition whereby the a-subunit (p19, Tfamily currently consists of IL-12, IL-23, p28, p35) and b-subunit (p40, Ebi3) are differ- IL-27, and IL-35 and these cytokines play im- entially shared to generate IL-12 (p40-p35), IL- portant roles in the development of appropriate 23 (p40-p19), IL-27 (Ebi3-p28), and IL-35 immune responses in various disease conditions (p40-p35) (Fig. 1A). Given their ability to share (Vignali and Kuchroo 2012). They act as a link a- and b-subunits, it has been predicted that between the innate and adaptive immune system combinations such as Ebi3-p19 and p28-p40 through mediating the appropriate differentia- could exist and serve physiological function tion of naı¨ve CD4þ T cells into various T helper (Fig.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Huil36g 169 Data Sheet
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin-36G (IL36G) is a pro-inflammatory cytokine that plays an important role in the pathophysiology of several diseases. IL36A, IL36B and IL36G; (formerly IL1F6, IL1F8, and IL1F9) are IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36B is secreted when transfected into 293-T cells and could constitute part of an independent signaling system analogous to that of IL1A and IL1B receptor agonist and interleukin-1 receptor type I (IL1R1). Furthermore, IL36G also can function as an agonist of NFκB activation through the orphan IL1- receptor-related protein 2. Recombinant human IL36G is synthesized as a protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site.There is a 53% amino acid homology between human and mouse IL36G. IL36G also has a 25-55% amino acid homology with IL36G and IL1RN, IL1B, IL36RN, IL36A, IL37, IL36B and IL1F10. Catalog Number 1110-36E Product Name IL36G (IL-36 gamma), Human (169 a.a.) Recombinant Human Interleukin-36γ IL36G, IL36γ Interleukin 1 Homolog 1 (IL1H1) Interleukin 1-Related Protein 2 (IL1RP2) Interleukin 1 Family, Member 9 (IL1F9) Source Escherichia coli MW 18.7 kDa (169 amino acids) Sequence MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND Accession Number Q9NZH8 Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA.
    [Show full text]
  • Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal
    Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site.
    [Show full text]
  • Association of an Interleukin 1B Gene Polymorphism (-511) With
    400 LETTER TO JMG Association of an interleukin 1B gene polymorphism (−511) with Parkinson’s disease in Finnish patients K M Mattila, J O Rinne, T Lehtimäki, M Röyttä, J-P Ahonen, M Hurme ............................................................................................................................. J Med Genet 2002;39:400–402 lzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative conditions Table 1 Genotype and allele frequencies of the IL1 characterised by the presence of abnormal accumula- gene cluster polymorphisms in AD, PD, and control A patients tion of proteins and loss of neurones in specific regions of the brain. The aetiology and pathogenesis of AD and PD still Controls remain largely unknown. Evidence has emerged that immune Polymorphism AD (n=92) PD (n=52) (n=73) mediated mechanisms may be important in the development − 12 IL1A ( 889) of these disorders, and cytokine interleukin 1 (IL1) is one of *1/*1 42 (0.46) 28 (0.54) 33 (0.45) the mediators suggested to be involved. *1/*2 39 (0.42) 20 (0.38) 29 (0.40) The IL1 family comprises three proteins, the proinflamma- *2/*2 11 (0.12) 4 (0.08) 11 (0.15) tory IL1α and IL1β and their inhibitor IL1 receptor antagonist *1 123 (0.67) 76 (0.73) 95 (0.65) *2 61 (0.32) 28 (0.27) 51 (0.35) (IL1Ra), which are encoded by the IL1A, IL1B, and IL1RN − genes respectively.3 Since IL1 may have a role in AD4–8 and in IL1B ( 511) 910 *1/*1 35 (0.38) 25 (0.48) 24 (0.32) PD, variation in the IL1A, IL1B, and IL1RN genes may be of *1/*2 47 (0.51) 25 (0.48) 30 (0.41) importance in the development of these disorders.
    [Show full text]
  • Genetic Determinants of Circulating Interleukin-1 Receptor Antagonist Levels and Their Association with Glycemic Traits
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Trepo - Institutional Repository of Tampere University GENETIC DETERMINANTS OF CIRCULATING INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS AND THEIR ASSOCIATION WITH GLYCEMIC TRAITS Marja-Liisa Nuotio Syventävien opintojen kirjallinen työ Tampereen yliopisto Lääketieteen yksikkö Tammikuu 2015 Tampereen yliopisto Lääketieteen yksikkö NUOTIO MARJA-LIISA: GENETIC DETERMINANTS OF CIRCULATING INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS AND THEIR ASSOCIATION WITH GLYCEMIC TRAITS Kirjallinen työ, 57 s. Ohjaaja: professori Mika Kähönen Tammikuu 2015 Avainsanat: sytokiinit, insuliiniresistenssi, tyypin 2 diabetes, tulehdus, glukoosimetabolia, genominlaajuinen assosiaatioanalyysi (GWAS) Tulehdusta välittäviin sytokiineihin kuuluvan interleukiini 1β (IL-1β):n kohonneen systeemisen pitoisuuden on arveltu edesauttavan insuliiniresistenssin kehittymistä ja johtavan haiman β-solujen toimintahäiriöihin. IL-1β:n sisäsyntyisellä vastavaikuttajalla, interleukiini 1 reseptoriantagonistilla (IL-1RA), on puolestaan esitetty olevan suojaava rooli mainittujen fenotyyppien kehittymisessä päinvastaisten vaikutustensa ansiosta. IL-1RA:n suojaavan roolin havainnollistamiseksi työssä Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits tunnistettiin veren IL-1RA- pitoisuuteen assosioituvia geneettisiä variantteja, minkä jälkeen selvitettiin näiden yhteyttä glukoosi- ja insuliinimetaboliaan liittyvien muuttujien-, sekä
    [Show full text]
  • Interleukin (IL)17A, F and AF in Inflammation: a Study in Collageninduced Arthritis and Rheumatoid Arthritis
    bs_bs_banner Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12376 Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis S. Sarkar,* S. Justa,* M. Brucks,* Summary J. Endres,† D. A. Fox,† X. Zhou,* Interleukin (IL)-17 plays a critical role in inflammation. Most studies to date F. Alnaimat,* B. Whitaker,‡ have elucidated the inflammatory role of IL-17A, often referred to as IL-17. J. C. Wheeler,‡ B. H. Jones§ and IL-17F is a member of the IL-17 family bearing 50% homology to IL-17A S. R. Bommireddy* and can also be present as heterodimer IL-17AF. This study elucidates the *Section of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, distribution and contribution of IL-17A, F and AF in inflammatory arthritis. University of Arizona, Tucson, AZ, †Divison of Neutralizing antibody to IL-17A alone or IL-17F alone or in combination Rheumatology, Department of Internal Medicine, was utilized in the mouse collagen-induced arthritis (CIA) model to eluci- University of Michigan, Ann Arbor, MI, and date the contribution of each subtype in mediating inflammation. IL-17A, F ‡Biologics Research and §Immunology Discovery and AF were all increased during inflammatory arthritis. Neutralization of Research, Janssen Research and Development, IL-17A reduced the severity of arthritis, neutralization of IL-17A+IL-17F had Spring House, PA, USA the same effect as neutralizing IL-17A, while neutralization of IL-17F had no effect. Moreover, significantly higher levels of IL-17A and IL-17F were detected in peripheral blood mononuclear cells (PBMC) from patients with rheumatoid arthritis (RA) in comparison to patients with osteoarthritis (OA).
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • Bioinformatics Identification of CCL8/21 As Potential Prognostic
    Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang ([email protected]) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC.
    [Show full text]
  • Interleukin 2 Medical Intensive Care Unit (4MICU)
    Interleukin 2 Medical Intensive Care Unit (4MICU) Ronald Reagan UCLA Medical Center 757 Westwood Plaza Los Angeles, CA 90095 Main Phone: (310) 267-7441 Fax: (310) 267-3785 About Our Unit The Medical Intensive Care Unit (MICU) cares Quick for critically ill patients in an intensive care Reference Guide environment, with nursing staff specially trained in the administration of Interleukin 2 therapy. Unit Director / Manager Mark Flitcraft, RN, MSN One registered nurse (RN) is assigned to take (310) 267-9529 care of a maximum of two patients. Our Medical Clinical Nurse Specialist Intensive Care Unit patient rooms are designed Yuhan Kao, RN, MSN, CNS (310) 267-7465 to allow nurses constant visual contact with their patients. As a safety precaution, the Medical Assistant Manager Sherry Xu, RN, BA, CCRN Intensive Care Unit is a closed unit and requires (310) 267-7485 permission to enter by intercom. Clinical Case Manager Each private-patient-care room contains the Connie Lefevre (310) 267-9740 most advanced intensive-care equipment available, including cardiac-monitoring and Clinical Social Worker Codie Lieto emergency-response equipment. The curtains in (310) 267-9741 the room will usually be drawn to keep your room Charge Nurse On-Duty more private. (310) 267-7480 or (310) 267-7482 A brief tour is available on weekdays for patients and visitors interested in walking through the unit Patient Affairs (310) 267-9113 and meeting the staff before arrival. To arrange for a tour, please call the nurse manager at Respiratory Supervisor (310) 267-9529. Orna Molayeme, MA, RCP, RRT, NPS (310) 267-8921 UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) About Our Unit During Your Stay Quick The Medical Team Reference Guide During each shift, you will be assigned a registered nurse (RN) and a clinical care partner (CCP).
    [Show full text]
  • Stimulation of Tumor Necrosis Factor Release from Monocytic Cells by the A375 Human Melanoma Via Granulocyte-Macrophage Colony-Stimulating Factor1
    [CANCER RESEARCH 50, 2673-2678. May 1, 1990] Stimulation of Tumor Necrosis Factor Release from Monocytic Cells by the A375 Human Melanoma via Granulocyte-Macrophage Colony-stimulating Factor1 Massimo Sabatini,2 Jeffery Chavez, Gregory R. Mundy, and Lynda F. Bonewald Division of Endocrinology and Metabolism, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284- 7877 ABSTRACT cell line A375, the target cell line used to show that GM-CSF induced monocyte-mediated cytoxicity (3), we noted that con It has long been known that complex interactions occur between tumors ditioned medium harvested from A375 tumor cell cultures and normal host immune cells. The human melanoma cell line A375 has been used previously as an indicator cell for tumor cell cytotoxicity induced TNF production in human blood monocytes and the mediated by monocytes. During other studies on this tumor cell line, we human monocytoid cell line U937 by the secretion of a soluble noted that the conditioned media harvested from A375 cultures induced factor. By multiple criteria, we have identified this soluble factor both the human monocytoid cell line U937 and human blood monocytes which causes TNF production as GM-CSF. These results sug to release the cytokine tumor necrosis factor (TNF). We characterized gest that in this human tumor, production of GM-CSF by the this tumor factor which induced TNF release by monocytic cells. Purifi tumor may retard tumor growth by causing release of cytotoxic cation was performed using ammonium sulfate precipitation, ion exchange cytokines of host cell origin. (DEAE) chromaiography, gel filtration, and reversed-phase high per formance liquid chromatography.
    [Show full text]